PUBLISHER: DataM Intelligence | PRODUCT CODE: 1290439
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1290439
Global Menopausal Hot Flashes Market - 2023-2030
Market Overview
The Global Menopausal Hot Flashes Market size reached US$ 13.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 20.5 billion by 2030. The Global Menopausal Hot Flashes Market is exhibiting at a CAGR of 5.5% during the forecast period 2023-2030.
The menopausal hot flashes market is driven by factors such as an increasing prevalence of menopausal hot flashes, growing incidence of menopausal hot flashes, a growing aging population, increasing awareness and understanding of menopause and its associated symptoms, increasing focus on women's health, advancements in treatment options, and changing lifestyles and preferences.
There are many restraints and challenges associated with the menopausal hot flashes market, including limited treatment efficacy, side effects of menopausal hot flashes drugs, high cost of the treatment, and so on.
Market Dynamics
Increasing Prevalence of Menopausal Hot Flashes
The increasing prevalence of menopausal hot flashes is a major factor driving the market share during the forecast period. The prevalence of menopausal hot flashes is increasing due to the aging women population, longer life expectancy, lifestyle changes like smoking, alcohol consumption, and junk food, hormonal changes, awareness and seeking treatment, and the need for effective management options and support for women during this stage of life.
The prevalence of hot flashes can vary among individuals, with some experiencing them more frequently and intensely than others. Healthcare providers and pharmaceutical companies are continuously working to develop and improve treatment options to alleviate the impact of hot flashes and enhance the quality of life for women experiencing this common menopausal symptom.
Side Effects of Menopausal Hot Flashes Drugs
The side effects associated with menopausal hot flashes drugs are a major factor hindering the market share. Menopausal hot flashes drugs, including hormonal and non-hormonal medications, can have potential side effects. It is important to note that not all individuals will experience these side effects, and the severity and frequency of side effects can vary.
COVID-19 Impact Analysis
The COVID-19 pandemic has significantly impacted various aspects of healthcare, including the management and treatment of menopausal hot flashes. During the pandemic, healthcare systems have faced significant challenges, including overwhelmed hospitals, staff shortages, and the need to redirect resources to the COVID-19 response. Non-urgent and elective healthcare visits, including those related to menopausal symptom management, have been postponed or canceled in some cases, leading to delays in diagnosis and treatment.
The COVID-19 pandemic has had a significant psychological impact on individuals worldwide. Stress, anxiety, and emotional disturbances resulting from the pandemic can exacerbate menopausal symptoms, including hot flashes. Women may require additional support and resources to manage the psychological and emotional effects of the pandemic on their menopausal symptoms.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict impacted the menopausal hot flashes market in the region. The conflict can strain the healthcare infrastructure in the affected regions. Disruptions in healthcare services, damaged medical facilities, and displacement of healthcare professionals can affect the availability and accessibility of healthcare, including menopausal symptom management.
The conflict, directly and indirectly, affected the menopausal hot flashes market due to the stress, disruptive environment during the war, and so on. This may hamper the women's access to healthcare services, including diagnosis and treatment of menopausal hot flashes.
Segment Analysis
The Global Menopausal Hot Flashes Market is segmented based on product, distribution channel, end-user, and region.
Hormonal Products are Expected to Dominate the Market Share
hormonal products are expected to dominate the market share, accounting for 47.2% during the forecast period. Hormonal products, such as estrogen therapy, progesterone therapy, or combined estrogen-progestin therapy, have been widely used for many years to manage menopausal symptoms, including hot flashes. These products work by supplementing the declining estrogen levels in the body during menopause, which can help alleviate hot flashes and other associated symptoms.
Hormonal products are often considered the most effective treatment option for menopausal hot flashes, providing significant relief for many women. They are available in various formulations, including oral tablets, patches, creams, gels, and vaginal rings, offering flexibility based on individual needs.
Geographical Analysis
North America Holds the Largest Market Share during the forecast period
North America holds the largest market share of 41.5% during the forecast period due to rising demand for menopausal hot flashes treatment. North America, which includes the United States and Canada, has a significant population of women in the menopausal age range, contributing to the demand for effective management of menopausal symptoms, including hot flashes.
Competitive Landscape
The major global players in the market include: Bayer AG, Novartis AG, Pfizer Inc, Novo Nordisk Corporation, AbbVie Inc. (Allergan Plc), Hisamitsu Pharmaceutical Co. Inc., Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Noven Pharmaceuticals, and AstraZeneca.
Why Purchase the Report?
- To visualize the Global Menopausal Hot Flashes Market segmentation based on product, distribution channel, end-user, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of menopausal hot flashes market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The Global Menopausal Hot Flashes Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Product
- 3.2. Snippet by Distribution Channel
- 3.3. Snippet by End-User
- 3.4. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing Prevalence of menopausal hot flashes
- 4.1.2. Restraints
- 4.1.2.1. Side effects of menopausal hot flashes drugs
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 & Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturer's Strategic Initiatives
- 6.6. Conclusion
7. By Product
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
- 7.2. Hormonal Products*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Estrogen
- 7.2.3.1. Premarin
- 7.2.3.2. Vivelle
- 7.2.3.3. Vivelle-Dot
- 7.2.4. Progesterone
- 7.2.4.1. Prometrium
- 7.2.5. Combination Products
- 7.2.5.1. Prempro
- 7.2.5.2. Duavee
- 7.3. Non-Hormonal Products
- 7.3.1.1. Brisdelle
- 7.3.1.2. Others
- 7.4. Others
8. By Distribution Channel
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Online Stores*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Retail outlets
- 8.4. Others
9. By End-User
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
- 9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Specialty Clinics
- 9.4. Academic & Research Institutes
10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. The U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. The UK
- 10.3.6.3. France
- 10.3.6.4. Italy
- 10.3.6.5. Spain
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. Australia
- 10.5.6.5. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
12. Company Profiles
- 12.1. Bayer AG*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Novartis AG
- 12.3. Pfizer Inc.
- 12.4. Novo Nordisk Corporation
- 12.5. AbbVie Inc. (Allergan Plc)
- 12.6. Hisamitsu Pharmaceutical Co. Inc.
- 12.7. Ferring Pharmaceuticals
- 12.8. Teva Pharmaceutical Industries Ltd.
- 12.9. Noven Pharmaceuticals
- 12.10. AstraZeneca
LIST NOT EXHAUSTIVE
13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
